DK1194528T3 - Monoklonalt antistof mod faktor VII, hvilket antistof selv ved forekomst i molært overskud kun delvist inaktiverer faktor VII, samt fremgangsmåde til produktion af et sådant antistof - Google Patents
Monoklonalt antistof mod faktor VII, hvilket antistof selv ved forekomst i molært overskud kun delvist inaktiverer faktor VII, samt fremgangsmåde til produktion af et sådant antistofInfo
- Publication number
- DK1194528T3 DK1194528T3 DK00949329T DK00949329T DK1194528T3 DK 1194528 T3 DK1194528 T3 DK 1194528T3 DK 00949329 T DK00949329 T DK 00949329T DK 00949329 T DK00949329 T DK 00949329T DK 1194528 T3 DK1194528 T3 DK 1194528T3
- Authority
- DK
- Denmark
- Prior art keywords
- ligands
- factor
- molar excess
- factor viii
- complex
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- Vascular Medicine (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14389199P | 1999-07-14 | 1999-07-14 | |
GBGB9916450.1A GB9916450D0 (en) | 1999-07-14 | 1999-07-14 | Ligands for use in therapeutic compounds for the treatment of hemostasis disorders |
PCT/EP2000/006677 WO2001004269A1 (en) | 1999-07-14 | 2000-07-13 | Ligands for use in therapeutic compositions for the treatment of hemostasis disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1194528T3 true DK1194528T3 (da) | 2007-07-09 |
Family
ID=26315767
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK00949329T DK1194528T3 (da) | 1999-07-14 | 2000-07-13 | Monoklonalt antistof mod faktor VII, hvilket antistof selv ved forekomst i molært overskud kun delvist inaktiverer faktor VII, samt fremgangsmåde til produktion af et sådant antistof |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP1194528B1 (ja) |
JP (2) | JP4297207B2 (ja) |
AT (1) | ATE356201T1 (ja) |
AU (1) | AU781638B2 (ja) |
CA (1) | CA2381125C (ja) |
CY (1) | CY1107638T1 (ja) |
DE (1) | DE60033814T2 (ja) |
DK (1) | DK1194528T3 (ja) |
ES (1) | ES2283308T3 (ja) |
PT (1) | PT1194528E (ja) |
WO (1) | WO2001004269A1 (ja) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7829085B2 (en) | 1999-07-14 | 2010-11-09 | Life Sciences Research Partners Vzw | Methods of treating hemostasis disorders using antibodies binding the C1 domain of factor VIII |
DE60236386D1 (de) | 2001-01-11 | 2010-07-01 | D Collen Res Foundation Vzw | Verfahren und pharmazeutische Zusammensetzung zur Vorbeugung und/oder Behandlung des Syndroms der systemischen entzündlichen Reaktion |
DE60230037D1 (de) * | 2001-06-12 | 2009-01-08 | Chemo Sero Therapeut Res Inst | Humanantikörper gegen blutgerinnungsfaktor viii |
EP1388544A1 (en) | 2002-07-31 | 2004-02-11 | D. Collen Research Foundation vzw | Anti-idiotypic antibodies against factor VIII inhibitor and uses thereof |
JP4422430B2 (ja) | 2003-05-14 | 2010-02-24 | 帝國製薬株式会社 | エストロゲン及び/又はプロゲストゲン含有外用貼付剤 |
US7785594B2 (en) | 2003-08-14 | 2010-08-31 | Life Sciences Research Partners Vzw | Factor VIII inhibitory antibodies with reduced glycosylation |
EP1910420B1 (en) * | 2005-07-29 | 2011-05-18 | Life Sciences Research Partners VZW | Human inhibitory anti-factor viii antibodies binding to the a2 domain |
FR2892724B1 (fr) | 2005-11-02 | 2008-01-04 | Lab Francais Du Fractionnement | Anticorps cytotoxiques diriges contre des anticorps inhibiteurs du facteur viii. |
FR2897868B1 (fr) * | 2006-02-24 | 2012-08-31 | Lab Francais Du Fractionnement | Anticorps anti-idiotypiques neutralisant l'activite inhibitrice d'un anticorps inhibiteur dirige contre le domaine c1 du facteur viii. |
RU2564131C2 (ru) | 2009-07-10 | 2015-09-27 | ТромбоДженикс НВ | Варианты плазминогена и плазмина |
US20120189609A1 (en) | 2009-08-28 | 2012-07-26 | Thrombogenics Nv | Improvement to trabeculectomy |
EP2661493B1 (en) | 2011-01-05 | 2016-03-30 | ThromboGenics N.V. | Plasminogen and plasmin variants |
JP6000353B2 (ja) | 2011-08-12 | 2016-09-28 | スロンボジェニックス・ナムローゼ・フェンノートシャップThromboGenics NV | プラスミノーゲンおよびプラスミンの変異体 |
AU2012321082B2 (en) | 2011-12-01 | 2015-03-12 | Oxurion NV | Improving trabeculectomy outcome |
KR101395736B1 (ko) * | 2012-07-10 | 2014-05-16 | 아주대학교산학협력단 | 인간 혈액응고인자 ⅷ 도메인 특이적 항체 및 이의 제조방법 |
AU2017231765A1 (en) | 2016-03-10 | 2018-08-23 | Oxurion NV | Posterior ocular fibrosis inhibition by antagonizing placental growth factor |
WO2018206734A1 (en) * | 2017-05-11 | 2018-11-15 | Vib Vzw | Glycosylation of variable immunoglobulin domains |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA24512A1 (fr) * | 1996-01-17 | 1998-12-31 | Univ Vermont And State Agrienl | Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose |
-
2000
- 2000-07-13 ES ES00949329T patent/ES2283308T3/es not_active Expired - Lifetime
- 2000-07-13 PT PT00949329T patent/PT1194528E/pt unknown
- 2000-07-13 DK DK00949329T patent/DK1194528T3/da active
- 2000-07-13 JP JP2001509473A patent/JP4297207B2/ja not_active Expired - Fee Related
- 2000-07-13 AU AU62730/00A patent/AU781638B2/en not_active Ceased
- 2000-07-13 AT AT00949329T patent/ATE356201T1/de active
- 2000-07-13 CA CA2381125A patent/CA2381125C/en not_active Expired - Fee Related
- 2000-07-13 DE DE60033814T patent/DE60033814T2/de not_active Expired - Lifetime
- 2000-07-13 WO PCT/EP2000/006677 patent/WO2001004269A1/en active IP Right Grant
- 2000-07-13 EP EP00949329A patent/EP1194528B1/en not_active Expired - Lifetime
-
2007
- 2007-05-24 CY CY20071100703T patent/CY1107638T1/el unknown
-
2008
- 2008-07-31 JP JP2008198354A patent/JP4297225B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CY1107638T1 (el) | 2013-04-18 |
DE60033814D1 (de) | 2007-04-19 |
JP4297225B2 (ja) | 2009-07-15 |
EP1194528B1 (en) | 2007-03-07 |
ES2283308T3 (es) | 2007-11-01 |
AU781638B2 (en) | 2005-06-02 |
CA2381125A1 (en) | 2001-01-18 |
EP1194528A1 (en) | 2002-04-10 |
JP2003504045A (ja) | 2003-02-04 |
CA2381125C (en) | 2013-04-23 |
ATE356201T1 (de) | 2007-03-15 |
JP2008295455A (ja) | 2008-12-11 |
DE60033814T2 (de) | 2007-11-08 |
AU6273000A (en) | 2001-01-30 |
JP4297207B2 (ja) | 2009-07-15 |
WO2001004269A1 (en) | 2001-01-18 |
PT1194528E (pt) | 2007-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1107638T1 (el) | Μονοκλωνο αντισωμα του παραγοντα viii που ακομη και οταν υπαρχει σε μοριακη περισσεια αδρανοποιει τον παραγοντα viii μονο εν μερει και μια μεθοδος παραγωγης ενος τετοιου αντισωματος | |
HK1068798A1 (en) | Antibodies for inhibiting blood coagulation and methods of use thereof | |
WO2010065077A3 (en) | Antagonists of il-6 to prevent or treat thrombosis | |
LU93265I2 (fr) | Eftrénonacog alfa ou un produit biosimilaire conformément à l'article 10(4) de la directive 2001/83/CE, tel que protégé par le brevet de base | |
ATE540976T1 (de) | Antikörper zur inhibierung der blutgerinnung und verfahren zur deren verwendung | |
DE69932084D1 (de) | Antikörperfragmente zur lokalen Behandlung von Augenerkrankungen | |
WO2002060955A3 (en) | Modified antibodies and methods of use | |
ATE434447T1 (de) | Zusammensetzungen und verfahren zur erzeugung von gefässeokklusion | |
EP2228389A3 (en) | Antibodies against vascular endothelial growth factor 2 | |
CY1108566T1 (el) | Ανοσολογικος ελεγχος των επιπεδων του b-αμυλοειδους in vivo | |
PT833911E (pt) | Anticorpos anti-factor tecidular enxertados com cdr e metodos para a sua utilizacao | |
CN110325211A (zh) | 采用抗因子XI/XIa抗体治疗的方法 | |
WO1999008109A3 (en) | Antibodies to oxidation-specific epitopes on lipoprotein and methods for their use in detecting, monitoring and inhibiting the growth of atheroma | |
CA2368670A1 (en) | Modulation of vascular permeability by means of tie2 receptor activators | |
WO2003093313A3 (en) | Antagonists of factor viii interaction with low-density lipoprotein receptor-related protein | |
WO2002074251A3 (en) | Monoclonal antibody therapy for pancreas cancer | |
Hansen et al. | Target-mediated clearance and bio-distribution of a monoclonal antibody against the Kunitz–type protease inhibitor 2 domain of tissue factor pathway inhibitor | |
HUP0301804A2 (hu) | Antitrombotikus ágensek | |
Gorkun et al. | Interactions mediated by the N-terminus of fibrinogen's Bβ chain | |
EP1334983A3 (de) | Inhibitorischer, monoklonaler Antikörper gegen die den Blutgerinnungsfaktor VII akitivierende Protease | |
Astermark et al. | Antibodies to factor VIIa in patients with haemophilia and high‐responding inhibitors | |
ATE374180T1 (de) | N-acylpyrrolidin-2-ylalkylbenzamidin-derivate als inhibitoren von factor xa | |
DE60128084D1 (de) | Verwendung von inaktives cln2 proenzym zur behandlung von lincl | |
DE60020970D1 (de) | Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf-erkrankungen | |
ATE222501T1 (de) | Tissue-faktor zur beeinflussung von gefässbildung |